170 related articles for article (PubMed ID: 35267618)
61. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.
Keleg S; Titov A; Heller A; Giese T; Tjaden C; Ahmad SS; Gaida MM; Bauer AS; Werner J; Giese NA
PLoS One; 2014; 9(6):e100178. PubMed ID: 24932730
[TBL] [Abstract][Full Text] [Related]
62. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Chen L; Liu YC; Zheng YY; Xu J; Zhang Y; Liu WL; Li ZY; Huang GD; Li WP
Phytother Res; 2019 Jun; 33(6):1736-1747. PubMed ID: 31006910
[TBL] [Abstract][Full Text] [Related]
63. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
64. [Clinicopathological analysis of 61 patients with rectal gastrointestinal stromal tumors].
Wu X; Jiang W; Zhang R; Ding P; Chen G; Lu Z; Li L; Fang Y; Wang F; Kong L; Lin J; Pan Z; Wan D
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):335-9. PubMed ID: 24760640
[TBL] [Abstract][Full Text] [Related]
65. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
66. Upregulation of Atoh1 correlates with favorable survival in gastrointestinal stromal tumor.
Huang H; Zhai X; Zhu H; Wang W; Zhang S; Wu L; Zhang J
Int J Clin Exp Pathol; 2014; 7(10):7123-30. PubMed ID: 25400808
[TBL] [Abstract][Full Text] [Related]
67. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.
Dupart JJ; Trent JC; Lee HY; Hess KR; Godwin AK; Taguchi T; Zhang W
Mol Cancer; 2009 Nov; 8():99. PubMed ID: 19903356
[TBL] [Abstract][Full Text] [Related]
68. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
69. Modern treatment of gastric gastrointestinal stromal tumors.
Roggin KK; Posner MC
World J Gastroenterol; 2012 Dec; 18(46):6720-8. PubMed ID: 23239909
[TBL] [Abstract][Full Text] [Related]
70. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202
[TBL] [Abstract][Full Text] [Related]
71. Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes.
Blay JY; Le Cesne A; Cassier PA; Ray-Coquard IL
Discov Med; 2012 May; 13(72):357-67. PubMed ID: 22642917
[TBL] [Abstract][Full Text] [Related]
72. The assessment of different risk classification systems for gastrointestinal stromal tumors (GISTs): the analytic results from the SEER database.
Zhao B; Zhang J; Mei D; Zhang J; Luo R; Xu H; Huang B
Scand J Gastroenterol; 2018; 53(10-11):1319-1327. PubMed ID: 30353759
[TBL] [Abstract][Full Text] [Related]
73. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.
Fenton M; Whiteside TL; Ferrone S; Boyiadzis M
Oncol Res; 2015; 22(2):117-21. PubMed ID: 25706398
[TBL] [Abstract][Full Text] [Related]
74. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
[TBL] [Abstract][Full Text] [Related]
75. Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.
Chantharasamee J; Adashek JJ; Wong K; Eckardt MA; Chmielowski B; Dry S; Eilber FC; Singh AS
Curr Treat Options Oncol; 2021 Jan; 22(1):9. PubMed ID: 33400014
[TBL] [Abstract][Full Text] [Related]
76. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
[TBL] [Abstract][Full Text] [Related]
77. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
78. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.
Schiffer D; Mellai M; Boldorini R; Bisogno I; Grifoni S; Corona C; Bertero L; Cassoni P; Casalone C; Annovazzi L
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213051
[TBL] [Abstract][Full Text] [Related]
79. Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome.
Lott S; Schmieder M; Mayer B; Henne-Bruns D; Knippschild U; Agaimy A; Schwab M; Kramer K
Am J Cancer Res; 2015; 5(1):333-43. PubMed ID: 25628942
[TBL] [Abstract][Full Text] [Related]
80. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
